[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100302988":3},{"organization":4,"outcomesModule":7,"designInfo":36,"detailedDescription":39,"studyPopulation":40,"armGroups":41,"interventions":51,"overallOfficials":55,"centralContacts":60,"locations":68,"responsibleParty":87,"collaborators":35,"id":90,"slug":35,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":35,"eligibilityCriteria":94,"healthyVolunteers":91,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":35,"studyType":101,"phases":35,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":71,"whyStopped":35,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Chongqing Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":35},[9],{"measure":10,"description":11,"timeFrame":12},"numbers of patients who develop cardiovascular events","compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension","1-15 years",[14,17,20,23,26,29,32],{"measure":15,"description":16,"timeFrame":12},"estimated glomerular filtration rate (eGFR)","Compare the incidence of hypertensive nephropathy between two groups (based on eGFR)",{"measure":18,"description":19,"timeFrame":12},"The incidence of new atrial fibrillation","Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension",{"measure":21,"description":22,"timeFrame":12},"The incidence of left ventricular hypertrophy","Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension",{"measure":24,"description":25,"timeFrame":12},"the variation of carotid intima-media thickness","Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension",{"measure":27,"description":28,"timeFrame":12},"subgroup analysis of cardiovascular events","Compare the cardiovascular and cerebrovascular risk between unilateral PA and idiopathic bilateral adrenal hyperplasia",{"measure":30,"description":31,"timeFrame":12},"quality of life score","Compare the quality of life between unilateral PA and idiopathic bilateral adrenal hyperplasia by the questionnaire.",{"measure":33,"description":34,"timeFrame":12},"Cardiovascular risk score","To investigate what kind of cardiovascular risk score can better predict cardiovascular risk of PA",null,{"allocation":35,"interventionModel":35,"interventionModelDescription":35,"primaryPurpose":35,"observationalModel":37,"timePerspective":38,"maskingInfo":35},"COHORT","PROSPECTIVE","This study will include the subjects of a series of studies on hypertension conducted by our team, including essential hypertension, PA subjects, and establish a large sample database and specimen bank through follow-up and omics analysis.","hypertensive patients who completed ARR screening and necessary further tests and Voluntary to be followed up will be included.",[42,47],{"label":43,"type":35,"description":44,"interventionNames":45},"Primary aldosteronism","screened, confirmed and subtyped according to the guidelines.",[46],"Other: no intervention",{"label":48,"type":35,"description":49,"interventionNames":50},"Essential hypertension","screened for PA and excluded the diagnosis of PA as well as other secondary hypertesion",[46],[52],{"type":6,"name":53,"description":53,"armGroupLabels":54,"otherNames":35},"no intervention",[48,43],[56],{"name":57,"affiliation":58,"role":59},"Qifu Li, phD","First Affiliated Hospital of Chongqing Medical University","STUDY_CHAIR",[61,65],{"name":57,"role":62,"phone":63,"phoneExt":35,"email":64},"CONTACT","+86 023-89011552","liqifu@yeah.net",{"name":66,"role":62,"phone":63,"phoneExt":35,"email":67},"Shumin Yang, phD","443068494@qq.com",[69],{"facility":70,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"Qifu Li","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":78,"coordinates":79},"Point",[80,81],106.55771,29.56026,{"lat":81,"lon":80},[84],{"name":85,"role":62,"phone":86,"phoneExt":35,"email":64},"Qifu Li, PhD","+86 23 89011552",{"type":88,"investigatorFullName":70,"investigatorTitle":89,"investigatorAffiliation":58,"oldNameTitle":35,"oldOrganization":35},"PRINCIPAL_INVESTIGATOR","Director of endocrinology","100302988",false,"NCT03224312","Chongqing Primary Aldosteronism Study","Inclusion Criteria:\n\n1. hypertensive patients who completed ARR screening and necessary further tests;\n2. Voluntary to sign the informed consent.\n\nExclusion Criteria:\n\n1. patients with severe cardiac, hepatic or renal dysfunction;\n2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.","ALL","18 Years","80 Years",{"count":99,"type":100},1500,"ESTIMATED","OBSERVATIONAL","We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.",[104],"Primary Aldosteronism",[43,106,107],"cardiovascular events","cerebrovascular events","2023-09-04",{"date":110,"type":111},"2023-09-06","ACTUAL",{"date":113,"type":111},"2016-10-01",{"date":115,"type":100},"2028-12-31",{"name":5,"class":6},1]